Affordable Access

Publisher Website

Radioprotectors and Mitigators of Radiation-Induced Normal Tissue Injury

Authors
Journal
The Oncologist
1083-7159
Publisher
Alphamed Press
Publication Date
Volume
15
Issue
4
Identifiers
DOI: 10.1634/theoncologist.2009-s104
Keywords
  • New Translational Research In Radiation Oncology: A Tribute To Eli Glatstein
Disciplines
  • Design
  • Medicine

Abstract

Radiation is used in the treatment of a broad range of malignancies. Exposure of normal tissue to radiation may result in both acute and chronic toxicities that can result in an inability to deliver the intended therapy, a range of symptoms, and a decrease in quality of life. Radioprotectors are compounds that are designed to reduce the damage in normal tissues caused by radiation. These compounds are often antioxidants and must be present before or at the time of radiation for effectiveness. Other agents, termed mitigators, may be used to minimize toxicity even after radiation has been delivered. Herein, we review agents in clinical use or in development as radioprotectors and mitigators of radiation-induced normal tissue injury. Few agents are approved for clinical use, but many new compounds show promising results in preclinical testing.

There are no comments yet on this publication. Be the first to share your thoughts.